Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sparano

Showing results (461-470 of 560) with videos related to

Pageof 56
Sort By:
The Oncologist|January 22, 2026
Everolimus as maintenance therapy in advanced neuroendocrine neoplasms: Results from the MAVERIC Phase II Trial (1499 WORDS MAIN TEXT)Lorenzo Antonuzzo, Daniele Lavacchi, Francesca Spada, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 25, 2018
Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103)Kathy D Miller, Anne O'Neill, William Gradishar, et al.
Frontiers in Genetics|December 16, 2024
PARP inhibitors in testicular germ cell tumors: what we know and what we are looking forSara Parola, Christoph Oing, Pasquale Rescigno, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2014
Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199Sylvia Adams, Robert J Gray, Sandra Demaria, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 21, 2016
Genome-Wide Association Study for Anthracycline-Induced Congestive Heart FailureBryan P Schneider, Fei Shen, Laura Gardner, et al.
Science Translational Medicine|July 7, 2017
Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanismGeorge S Karagiannis, Jessica M Pastoriza, Yarong Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 10, 2017
Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205)Madhur K Garg, Fengmin Zhao, Joseph A Sparano, et al.
Cancer Discovery|May 3, 2020
Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital SystemVikas Mehta, Sanjay Goel, Rafi Kabarriti, et al.
Immunity|August 1, 2025
Mutations in MLL3 promote breast cancer progression via HIF1α-dependent intratumoral recruitment and differentiation of regulatory T cellsMarie Boutet, Kenta Nishitani, Nicole Couturier, et al.
Journal of Clinical Medicine|February 27, 2026
Analysis of a Real-World Population Participating in a Cardiac Rehabilitation Program: Cognitive Impairment, Functional Capacity, and Therapy TitrationNicola Virtuoso, Francesca Palmieri, Francesco Loria, et al.
Pageof 56

Showing results (461-470 of 560) with videos related to

Sort By:
Pageof 56
The Oncologist|January 22, 2026
Everolimus as maintenance therapy in advanced neuroendocrine neoplasms: Results from the MAVERIC Phase II Trial (1499 WORDS MAIN TEXT)Lorenzo Antonuzzo, Daniele Lavacchi, Francesca Spada, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 25, 2018
Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103)Kathy D Miller, Anne O'Neill, William Gradishar, et al.
Frontiers in Genetics|December 16, 2024
PARP inhibitors in testicular germ cell tumors: what we know and what we are looking forSara Parola, Christoph Oing, Pasquale Rescigno, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2014
Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199Sylvia Adams, Robert J Gray, Sandra Demaria, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 21, 2016
Genome-Wide Association Study for Anthracycline-Induced Congestive Heart FailureBryan P Schneider, Fei Shen, Laura Gardner, et al.
Science Translational Medicine|July 7, 2017
Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanismGeorge S Karagiannis, Jessica M Pastoriza, Yarong Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 10, 2017
Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205)Madhur K Garg, Fengmin Zhao, Joseph A Sparano, et al.
Cancer Discovery|May 3, 2020
Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital SystemVikas Mehta, Sanjay Goel, Rafi Kabarriti, et al.
Immunity|August 1, 2025
Mutations in MLL3 promote breast cancer progression via HIF1α-dependent intratumoral recruitment and differentiation of regulatory T cellsMarie Boutet, Kenta Nishitani, Nicole Couturier, et al.
Journal of Clinical Medicine|February 27, 2026
Analysis of a Real-World Population Participating in a Cardiac Rehabilitation Program: Cognitive Impairment, Functional Capacity, and Therapy TitrationNicola Virtuoso, Francesca Palmieri, Francesco Loria, et al.
Pageof 56